Zika virus infection future or investigational therapies

Sexually transmitted diseases Main Page
Zika virus infection Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Classification
Differentiating Zika Virus Infection from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications, and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Evaluation of Pregnant Women
Evaluation of Infants
Collection and Submission of Fetal Tissues
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Guidelines for Pregnant Women
Travel Notice
Blood Donation
Sexual transmission
Secondary Prevention
CDC Response Planning Tips
Risk-based Preparedness for States
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Zika virus infection future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Zika virus infection future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Zika virus infection future or investigational therapies
CDC on Zika virus infection future or investigational therapies
Zika virus infection future or investigational therapies in the news
Blogs on Zika virus infection future or investigational therapies
Directions to Hospitals Treating Zika virus infection
Risk calculators and risk factors for Zika virus infection future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Nate Michalak, B.A.

Overview

There is currently no vaccine in advanced development to prevent Zika virus infection.

Future or Investigational Therapies

• There is currently no vaccine in advanced development to prevent Zika virus infection.
• It is unknown if vaccines against other flaviviruses are effective against Zika virus. The efficacy and safety of vaccines currently under development against Chikungunya virus are being studied in pre-clinical experiments for Zika virus.[2]
• In February 2016, Sanofi, Pfizer, Johnson and Johnson, Merck,and Takeda announced the launching of projects to develop vaccines against Zika virus using either new technologies or existing vaccines.[3][4]
• Recent animal studies have shown that human monoclonal antibodies against Zika virus envelope (E) protein, isolated from individuals with prior Zika virus infection, reduce tissue pathology, maternal-fetal transmission, and mortality when injected in mice.